G7 Summit 2026 to Focus on Middle East Conflicts, Ukraine War, and Global Economic Challenges 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Steve Hilton and Xavier Becerra Advance to California Governor Election After Primary Results 
Venezuela Deploys Troops to Crack Down on Illegal Gold Mining Amid Push for Foreign Investment 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
DOJ Sues Virginia Over Law Enforcement Mask Ban 
Lebanon Resists Iran Pressure as Israel-Hezbollah Ceasefire Talks Stall 
US Voters Prioritize Party Loyalty Over Candidate Controversies, Reuters/Ipsos Poll Finds 
Trump Nears Decision on Permanent U.S. Intelligence Chief as FISA Renewal Faces Senate Resistance 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
